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a b s t r a c t
Malaria parasites are frequently polymorphic at the antigenic targets of many candidate vaccines, pre-
sumably as a consequence of selection pressure fromprotective immune responses. Conventionalwisdom
is therefore that vaccines directed against a single variant could select for non-target variants, rendering
the vaccine useless. Many people have argued that a solution is to develop vaccines containing the prod-
ucts of more than one variant of the target. However, we are unaware of any evidence that multi-allele
vaccines better protect hosts against parasites or morbidity. Moreover, selection of antigen-variants is not
the only evolution that could occur in response to vaccination. Increased virulence could also be favored
if more aggressive strains are less well controlled by vaccine-induced immunity. Virulence and antigenic
identity have been confounded in all studies so far, and so we do not know formally from any animal
or human studies whether vaccine failure has been due to evasion of protective responses by variants at
target epitopes, or whether vaccines are just less good at protecting against more aggressive strains.
Using the rodent malaria model Plasmodium chabaudi and recombinant apical membrane antigen-1
(AMA-1), we tested whether a bi-allelic vaccine afforded greater protection from parasite infection and
morbidity than did vaccination with the component alleles alone. We also tested the effect of mono-
and bi-allelic vaccination on within-host selection of mixed P. chabaudi infections, and whether parasite
virulence mediates pathogen titres in immunized hosts. We found that vaccination with the bi-allelic
AMA-1 formulationdidnot afford thehost greater protection fromparasite infection ormorbidity thandid
mono-allelic AMA-1 immunization. Mono-allelic immunization increased the frequency of heterologous
clones in mixed clone infections. There was no evidence that any type of immunization regime favored
virulence. A single AMA-1 variant is a component of candidate malaria vaccines current in human trials;
our results suggest that adding extra AMA-1 alleles to these vaccines would not confer clinical beneﬁts,
but that that mono-allelic vaccines could alter AMA-1 allele frequencies in natural populations.
© 2008 Elsevier Ltd. All rights reserved.
1. Introduction
Malaria parasite antigens which are the targets of protective
immune responses are frequently polymorphic, with antigen-
coding genes having multiple allelic forms [1]. Polymorphisms
likely arise as a consequence of immune-mediated selection
because host responses can be more effective against parasites of
the immunising strain than against different strains (strain-speciﬁc
immunity) [2–6]. Sequence polymorphisms have been directly
∗ Corresponding author at: Centre for Infectious Disease Dynamics, Depart-
ments of Biology and Entomology, The Pennsylvania State University, University
Park 16802, USA. Tel.: +1 8148639330.
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implicated in antigenic escape [7–9], and inmalaria endemic areas,
immunity is acquired slowly, probably because repeated exposure
is required to generate an effective response against a repertoire
of strains [10–12]. The existence of antigenic polymorphism is
therefore of considerable concern to malaria vaccine developers
because it implies that single antigen vaccines will have trou-
ble inducing protective immunity against polymorphic targets
[13–16].
One approach to minimizing vaccine-induced strain-speciﬁcity
has been to design vaccines which combine more than one allele of
anantigen [1,17–19].However, the inclusionofmore thanoneallelic
form of an antigen may not be sufﬁcient to overcome substantial
polymorphisms [9], and there is little experimental evidence that
multi-allele vaccines actually afford the host more protection from
morbidity than do single antigen vaccines.
0264-410X/$ – see front matter © 2008 Elsevier Ltd. All rights reserved.
doi:10.1016/j.vaccine.2008.09.004
6100 V.C. Barclay et al. / Vaccine 26 (2008) 6099–6107
Furthermore, selection of antigen-variants is not the only evo-
lution that could occur in response to widespread vaccination.
Theoretically, vaccination has the potential to cause evolution-
ary change in parasite virulence (parasite-induced host damage)
by altering the way natural selection acts on parasite popula-
tions [20–27]. In experimental evolution experiments, the rodent
malaria Plasmodium chabaudi became virulent more rapidly if
serially passaged through mice previously immunized with live
parasites [28]. The most likely explanation for this is that more
aggressive variants are less well controlled by immunity.
To date, we still do not fully understand how vaccines will
alter gene frequencies in malaria parasite populations. Evidence
for selection in the ﬁeld comes from a small phase 1-2b trial of
the “Combination B” blood-stage malaria vaccine [29]. This vaccine
contained a single antigen from each of three polymorphic loci of
P. falciparum. One of these loci, merozoite surface protein-2 (MSP-
2), is dimorphic, with each parasite having an allele from one of
two allelic families (labelled 3D7 and FC27). TheMSP-2 allele in the
Combination B vaccine came from the 3D7 family. Among parasites
subsequently acquired by vaccines, 3D7-type alleles were rarer
than in people given a placebo. Vaccination thus selected against
the variant contained in the vaccine. Interestingly, the FC27 allelic
family is associated with more virulent infections [30]. Therefore,
it is not clear whether the vaccine-imposed selection was due to
immune speciﬁcity [15,31] or whether the vaccine was less good at
controlling more virulent infections.
Many candidate vaccines against malaria are directed against
the asexual blood stage, with the principal target being the mero-
zoite. Apical merozoite antigen-1 (AMA-1) is a promising vaccine
candidate as it possesses fewer polymorphisms than other mero-
zoite antigens [2,13]. AMA-1 is thought to play a major role
during erythrocyte re-modelling and invasion [32]. Immuniza-
tion with AMA-1 confers protection against parasite challenge
in a number of animal models, probably by inducing antibod-
ies which inhibit invasion [2,7,33–36]. Furthermore, humans and
other species immunized with single allele AMA-1 vaccines raise
antibodies which inhibit erythrocyte invasion in vitro [13,37]. In
endemic populations, naturally acquired antibody to P. falciparum
AMA-1 (PfAMA-1) is associated with protection from falciparum
malaria [38–42]. At least six different vaccines based on the AMA-
1 allele from the P. falciparum 3D7 strain are currently in efﬁcacy
trials in humans [43–45].
However, there are more than 60 polymorphic sites in the AMA-
1 protein, and most of these are non-randomly dispersed point
mutations on domain I [46–50]. These point mutations may be
of immunological importance. Protection in mice is strain-speciﬁc,
and growth and invasion inhibition assays (GIA) and ELISA show
that antibodies from animals and human ﬁeld sera inhibit growth
in a strain-speciﬁc manner [2,13,34,38,43,47]. Allelic replacement
experiments have directly implicated sequence polymorphism in
antigenic escape [7], and cross-strain inhibition assays suggest that
the extent of escape correlates with sequence distance between
the vaccine and the target strain [8]. In an attempt to overcome
strain-speciﬁcity, vaccine researchers are beginning to combine
allelic variants of AMA-1. For example, one group immunized rhe-
sus monkeys with a mixture of two allelic forms of PfAMA-1
(designated AMA-1-C1) or the component alleles and measured
responses in vitro using GIA and ELISA [8,51,52]. The resulting anti-
bodieswere similarly effective regardlessofwhether immunization
was with a single variant or AMA-1-C1. Another group immunized
mice and rabbits with two allelic variants of domain I and II of
AMA-1 ectodomain from P. falciparum isolates. The anti-AMA-1
antibodies obtained with both proteins were active in an in vitro
parasite growth invasion/inhibition assay, but to no greater extent
than with either of the variants alone [53]. Together these results
have raised questions about the necessity of using multi-allele vac-
cines.
Here we use the rodent malaria P. chabaudi and two alleles of
the blood-stage malaria vaccine candidate AMA-1 to investigate (i)
whether immunization with a single or bi-allelic AMA-1 variant
formulation afforded the host the greatest protection from mor-
bidity and parasite infection, (ii) how these different vaccination
regimes can alter clonal frequencies in mixed infections, and (iii)
whether more virulent clones are better at evading heterologous
vaccine-induced protective responses.
2. Materials and methods
2.1. Parasites and hosts
P. chabaudi adami clones were originally derived from wild-
caught thicket rats (Thamnomys rutilans) in the Congo and stored
as frozen stabilites in liquid nitrogen with subscript codes used to
identify their position in clonal history [54,55]. In this experiment
we used clones DS500 and DK122 originally cloned from isolates
408XZ and556KA, respectively. The nucleotide sequences of theDK
andDS P. chabaudiAMA-1 (PcAMA-1) gene differ at 79 sites [34,56].
Hosts were inbred female C57BL/6 mice aged 6–8 weeks (Harlan,
England) maintained as described previously [57]. Studies by oth-
ers [34] and our ownpilot studies showed that these clones differ in
virulence during the infection of C57BL/6 female mice, with clone
DS generating substantially more parasites and inducing greater
weight and red blood cell loss relative to DK.
2.2. Immunizations and isotype ELISA
Here we used an immunization protocol adapted from Anders
et al. [2]. Prior to immunization, mice were randomized into four
groups of eighteen (Table 1). Immunization was with the highly
immunogenic ectodomian of the full AMA-1 protein termed AMA-
1B. For mono-allelic immunizations (hereafter referred to as DS
AMA-1 or DK AMA-1), groups of mice were injected intraperi-
toneally with 10g of the appropriate protein emulsiﬁed in 100l
of the adjuvant Montanide ISA720 (Seppic, France). For bi-allelic
immunizations, mice were injected with a mixture of 5g of both
DS and DK AMA-1, giving the same total dose of antigen as for
the single antigen immunizations, again emulsiﬁed in Montanide
ISA720. Control mice were injected with 100l emulsion of PBS in
Montanide ISA720. Mice were given a single booster immunization
with the same amount of antigen emulsiﬁed in Montanide ISA720
4 weeks after the primary immunization.
To ensure that antigen immunization successfully generated
antibody responses, and to determine whether there was any
cross-reactivity between the antibodies generated to the differ-
ent immunizing antigens, we ﬁrst carried out a pilot experiment.
A total of 11 mice were immunized with DS AMA-1, 11 with DK
AMA-1, and 10 were sham-immunized. We estimated the quan-
tity of IgG2b antigen-speciﬁc antibodies in all mice sera 11 days
after the booster immunization by ELISA using wells coated with
DS AMA-1 or DK AMA-1. Thus the sera from 32 mice were tested in
64wells.Weused IgG2b as previouswork in our laboratory showed
that C57BL/6 produce this isotype in response to P. chabaudi infec-
tion (K. Grocock, A. Graham, unpublished). Protection induced by
immunization with recombinant AMA-1 is isotype independent
[58b]. Given the lack of cross-reactivity we observed in this pilot
experiment (see Section 3), in the main experiment, we measured
IgG2b isotype antibodies to each antigen separately only from the
sera of mice immunized with a mixture of DS and DK AMA-1 and
in sham-immunized control mice.
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Table 1
Experimental design
Number of mice per immunization Infecting clone Number of mice per parasite infection Number of deaths Number of euthanized
Sham-immun
18
DS 6 3 2
Sham-immun DK 6
Sham-immun DS+DK 6
DK AMA-1
18
DS 6
DK AMA-1 DK 6
DK AMA-1 DS+DK 6
DS AMA-1
18
DS 6 1
DS AMA-1 DK 6
DSAMA-1 DS+DK 6 1
Bi-allelic
18
DS 6 2 1
Bi-allelic DK 6
Bi-allelic DS+DK 6
Total 72 72 7 3
Immunization was either with DK AMA-1, DS AMA-1, a formulation containing an equal mix of both forms of AMA-1 (bi-allelic), or immunization with adjuvant only
(‘sham-immunization’). Groups of 18 mice were immunized with one of the four treatments before being separated into groups of 6. Infection was with parasites of clone
DK alone, clone DS alone or a mixture of both. During the experiment 7 mice were found dead and 3 had to been euthanized due to severe morbidity. Euthanization was at
predetermined levels of morbidity prescribed by animal care protocols.
In both the pilot and main experiments, sera fractions were
separated by centrifugation from 20l of blood taken from a tail
snip and were stored at −80 ◦C. High binding 96 well ELISA Max-
isorb immunoplates (Nunc) were coated with either DS AMA-1
or DK AMA-1 at a concentration of 1g/ml in 0.06M carbonate
buffer (0.04M NaHCO3, 0.02M NaCO3, pH 9.6) in a ﬁnal volume of
50l perwell. Plateswere stored at 4 ◦Covernight to allow the anti-
gen to bind. Non-speciﬁc binding was blocked by incubating wells
with 5% BSA: carbonate buffer (200l per well) for 2h at 37 ◦C.
Wells were then washed three times in Tris buffered saline with
0.01% Tween 20 (TBST). We used end-point dilution methods to
detect IgG2b titres: serum samples were detected in a serial dilu-
tion 1/100-1/204800 using TBST as a diluent, in a ﬁnal volume of
50l per well and incubated for 2h at 37 ◦C. Wells were washed
three times in TBST. HRP conjugated goat anti-mouse IgG2b detec-
tion antibody (Southern Biotech 1100-05) was diluted 1/4000 in
TBST to a ﬁnal volume of 50l per well. Plates were incubated for
1h at 37 ◦C. Wells were washed three times in TBST followed by
a ﬁnal wash in distilled water. ABTS peroxide substrate (Insight
Biotechnology)wasaddedat100l perwell andallowed todevelop
at room temperature for 20min. Optical densitywas read at 405nm
using a spectrophotometer. IgG2b isotype antibody titres were cal-
culated as the reciprocal of the greatest dilution at which optical
density (O.D.) was greater than the mean (plus 2 standard devia-
tions) O.D. values observed for naïve mouse sera assayed against
both DS and DK AMA-1 at 1/100.
2.3. Parasite challenge and monitoring of within-host dynamics
Two weeks after the boost immunization, groups of immu-
nized mice (18 per group) were further randomized into groups
of six and challenged with 105 parasites of either clone DS alone,
clone DK alone or a mixture of clone DS and DK (Table 1).
Thus, mice infected with both clones received twice as many
parasites as those infected with one clone. A two-fold differ-
ence in infective dose has negligible effects on the population
dynamics of the parasite [58a]. During the course of infection,
we measured body weights and took blood samples from the
tail to (i) make Giemsa-stained blood smears, (ii) estimate red
blood cell density by ﬂow cytometry (Beckman Coulter), and (iii)
for genotype-speciﬁc real-time quantitative PCR (qPCR) assays as
described previously [59]. For ampliﬁcation of the DK genotype,
we used primers previously designed to amplify AS/AJ genotypes
as described elsewhere [59]. DS genotype-speciﬁc primers were as
follows: DS forward 5′-GGA AAA GGT ATA ACT AAT CAA AAA TCT
ACT AAA-3′; DS reverse 5′-CAG GAG AAA TGT TTA CAT CTG CTT
T-3′.
2.4. Trait deﬁnition and statistical analyses
Since P. chabaudi has a 24-h replication cycle, the total number
of parasites present in any period can be estimated by summing
the daily parasite counts. Data were analysed using General Linear
Models (GLMs) in MINITAB. To meet normality and homogene-
ity of variance assumptions, data on antibodies, weight and red
blood cell density were log transformed while all parasite den-
sities and proportions were square root transformed. GLMs were
used to test whether the magnitude of protection differed between
the three antigen immunizations (DK AMA-1, DS AMA-1, or the
bi-allelic form); that is whether there was a statistical interac-
tion between infecting clone and immunizing treatments.Maximal
models (response variable = infecting clone+ immunizing treat-
ment + infecting clone× immunization treatment) were tested in
the ﬁrst instance, and minimal models were obtained by drop-
ping non-signiﬁcant terms successively, beginning with highest
order interactions, to obtain the signiﬁcant minimal model. For
analyses of within-host selection, we asked for mixed clone infec-
tions, whether the frequency of clone DS in the parasite population
differed between the sham-immunized controls and the antigen
immunizations.
3. Results
Table 1 gives details of the immunization treatments, infecting
clone and sample size of the experiment. Some mice died; these
were included in thecalculationofdailydensitiesuntil death, and in
the analyses of peak parasite densities since death always occurred
as initial parasiteamias were declining.
3.1. Pre-challenge anti-AMA-1 IgG2b antibodies
Fig. 1 illustrates the data from a pilot experiment where IgG2b
antigen-speciﬁc antibodies were measured to each of the immu-
nizing antigens and the cross-reactivity between them. All antigen
immunization treatments generated antibody titres that were
higher than those present in sham-immunized controls (sham-
immunized versus antigen immunized: F1,62 = 8.92, p=0.004).
IgG2b antibodies were speciﬁc for the antigen they had been
exposed to during immunization (immunizing treatment×ELISA
antigen: F1,40 = 9.99, p=0.003). For example, anti-DS AMA-1 IgG2b
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Fig. 1. IGg2b antibody levels from the serum of mice in the pilot experiment. Mice
were either sham-immunized or immunisedwith one of the two atingens (DS AMA-
1, DK AMA-1). Each of the treatments used to immunize mice and the AMA-1 test
antigen used to coat ELISA plates are shown on the x-axis. Dots represent the anti-
body titre against a particular immunizing antigen for a single mouse. Horizontal
lines indicate mean antibody levels. Antibody levels in antigen immunized groups
of mice were higher than in sham-immunized controls (p<0.001) and, among the
immunized mice, the levels induced between the antigen immunized groups dif-
fered (immunizing treatment×ELISA antigen: p=0.003) with higher titres against
the homologous antigen. Neither of the immunising antigens induced higher titres
(p>0.05).
antibody tires were higher when assayed against the homologous
DS antigen than the heterologous DK antigen and vice versa. Thus,
neither antigen elicited a stronger response overall.
Fig. 2 illustrates the IgG2b antibody titres in mice from the main
experiment 3 days prior to parasite infection. All antigen immu-
nization treatments induced antibody titres that were higher than
those present in sham-immunized mice (sham-immunized versus
immunized: F1,106 = 58.89, p<0.001). Among antigen-immunized
groups, titres did not differ (F2,69 = 2.56, p=0.085). In those mice
which had been immunized with the bi-allelic form, antibodies
were not more speciﬁcally recognising either component antigen
(F1,35 = 0.61, p=0.44). These data show that immunization success-
fully elicited antibody responses, and that, at least as measured by
IgG2b titres, these responses were of equal magnitude in all immu-
Fig. 2. IgG2b antibody levels from the serum of mice in the main experiment. Mice
were either sham-immunized, or immunized with one of the antigen immuniza-
tion treatments (DS AMA-1, DK AMA-1 or the bi-allelic formulation). Each of the
treatments used to immunize mice and the AMA-1 test antigen used to coat ELISA
plates are shown on the x-axis. Dots represent the antibody titre for individual mice
against a particular antigen. Mice that were sham-immunized or immunized with
the bi-allelic formulation were assayed for antibody responses against both DS and
DK AMA-1 antigens. Horizontal lines indicate mean antibody levels. Antibody levels
in antigen immunizedgroupsofmicewerehigher than in sham-immunized controls
(p<0.001), and among the antigen immunized mice, antibody titres did not differ
(p=0.085). The antibody titres in animals immunized with both antigens were not
dominated by responses to either one (p=0.44).
nized groups. Among antigen-immunized mice, antibody titres
prior to challenge did not predict subsequent parasite intensities,
weight loss or anaemia (all correlations, p>0.2).
3.2. Bi-allelic immunization did not generate a greater
anti-morbidity response than did mono-allelic immunization
Red blood cell density and weight kinetics following parasite
challenge for each of the immunization treatments are illustrated
in Fig. 3A–F, and theminimum red blood cell density andminimum
weight reached are illustrated in Fig. 3G–H. In sham-immunized
control mice, clone DK was less virulent than clone DS, induced
less anaemia and less weight loss (Fig. 3A–H; anaemia: F2,14 = 6.29,
p=0.011; weight loss: F2,14 = 9.97, p=0.002).
Immunization protected mice against anaemia induced by
infection with any of the clones (Fig. 3A–C, G; sham-immunized
versus immunized: F1,69 = 16.94, p<0.001). Bi-allelic immunization
reduced anaemia no more than did immunization with either of
the alleles alone (Fig. 3G; immunizing treatment× infecting clone:
F4,44 = 0.71, p=0.59). All pairwise immunization comparisons were
non-signiﬁcant (p>0.5 in all cases).
As infection with clone DK did not induce any weight loss in
sham-immunized controls (Fig. 3D) the protective effects of immu-
nization were analysed only for infections that contained clone DS
(Fig. 3E–F).We found that all immunizationsprotectedmice against
weight loss due to DS infections (Fig. 3E–F, H; sham-immunized
versus immunized: F1,45 = 11.13, p=0.002). Similar to the anaemia
data, we found that immunization with either the bi-allelic form
or either of the alleles alone afforded similar levels of protec-
tion againstweight loss (Fig. 3H; immunizing treatment× infecting
clone: F2,29 = 2.43,p=0.11). All pairwise immunization comparisons
were non-signiﬁcant (p>0.5 in all cases).
Together, these results show that immunization with the bi-
allelic vaccine does not afford the host greater protection from
morbidity, as measured by anaemia and weight loss. Immuniza-
tion with either of the variants alone provided protection which
was as effective as that induced by the two variants together.
3.3. Bi-allelic immunization did not generate greater
anti-parasite response than did mono-allelic immunization
Parasite dynamics under each of the treatments are illus-
trated in Fig. 4. Clone DS achieved higher parasite density in
sham-immunized control mice than did clone DK (infecting clone:
F1,10 = 7.03=0.024).
All three immunizations reduced peak parasite densities rel-
ative to those which had received a sham inoculation (Fig. 4D;
sham-immunized versus immunized: F1,69 = 11.55, p=0.001). The
extent of anti-parasite protection depended on the identity of the
immunising antigenand the identity of the challenge clone (Fig. 4D;
immunizing treatment× infecting clone: F4,44 = 8.71, p<0.001). We
found that protection was clone-speciﬁc: immunization with DS
AMA-1 antigen reduced DS parasite densities more than it reduced
the densities of clone DK, and vice versa (among single anti-
gen immunized groups, immunizing treatment× infecting clone:
F1,19 = 36.26, p<0.001).
When we compared the extent of anti-parasite protection
between the immunized groups we found that under no circum-
stances did the bi-allelic immunization afford greater protection
than did immunization with a single allele. For example, immu-
nization with DS AMA-1 reduced the peak density of DK infections
and infections with both clones together, but the bi-allelic
immunization did not protect against DS alone (Fig. 4D; immu-
nizing treatment× infecting clone: F2,30 = 9.84, p=0.001). Although
the bi-allelic immunization reduced the densities of clone DK,
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Fig. 3. Effect of Plasmodium chabaudi infection (clone DK alone, DS alone or DS+DK) and immunization (sham-immunized control, DK AMA-1, DS AMA-1, or bi-allelic form)
on the kinetics of minimum red blood cell density (left panels) and minimum weight (right panels). In A–F lines represent the change in RBC density (left panels) and weight
(right panels) over time. Each line represents the mean of up to 6 mice (±1S.E.M.) that were infected with DK alone (A and D), DS alone (B and E) or a mixed clone (C and F)
infection during immunization with either a sham-inoculation control (solid thick black line), DK AMA-1 (open triangle), DS AMA-1 (open squares), or the bi-allelic mixture
(dotted black line). In G–H bars represent the minimum red blood cell density (left panel) and minimum weight (right panel) reached during infection with clone DK alone
(grey bars), DS alone (black bars) or a mixture of both clones (black and white bars) under each of the immunization treatments. Each bar represents the least squares mean
of up to 6 mice (±1S.E.M.).
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Fig. 4. Kinetics of P. chabaudi infections (clones DK alone, DS alone or both together)
following immunization (DK AMA-1, DS AMA-1, or bi-allelic formulation or sham-
immunized control). In A–C, lines represent the change in parasite density over time.
Each line represents the mean of up to 6 mice (±1S.E.M.) that were infected with
DK alone (A), DS alone (B) or a mixed clone (C) infection during immunization with
either a sham-inoculation control (solid thick black line), DK AMA-1 (open triangle),
DS AMA-1 (open squares), or the bi-allelic mixture (dotted black line). In (D), bars
represent peakparasite densities reachedduring infectionwith cloneDKalone (grey
bars), DS alone (black bars) or a mixture of both clones (black and white diagonal)
under each of the immunization treatments. Each bar represents the least squares
mean of up to 6 mice (±1S.E.M.).
reduction was no greater than with a single DK AMA-1 immuniza-
tion (Fig. 4D; immunizing treatment× infecting clone F2,29 = 4.09,
p=0.027).
Together these results show that bi-allelic immunization did
not afford the host greater anti-parasite protection than did
mono-allelic immunization. Unlike morbidity, where protection
Fig. 5. Proportion of clone DS in mixed DS and DK infections following immuniza-
tion with DK AMA-1, DS AMA-1, the bi-allelic formulation, or in sham-immunized
controls. (A) Lines represents the proportion of clone DS through time in control
(solid black line), DK AMA-1 (open triangles), DS AMA-1 (open diamonds) or bi-
allelic (dotted black line) immunized mice. Each line represents the mean of up
to 6 mice (±1S.E.M.). (B) Bar graphs represent the proportion of total parasites in
a mixed infection that were DS under each of the immunization treatments. Each
bar represents the least squares mean of up to 6 mice with 95% conﬁdence inter-
vals. The black horizontal dotted line represents the proportion DS present in the
inoculum.
was induced regardless of the antigen used in immunization,
we found that immunization with a single allele achieved better
protection against the homologous clone, and bi-allelic immu-
nization never did as well. Indeed, we found just one of the
variants (DS AMA-1) to be the most effective at reducing parasite
densities.
3.4. Vaccine-induced anti-parasite protection was clone speciﬁc
in mixed infections and independent of clone virulence
To examine how the antigenic composition of the immuniz-
ing formulation affects within-host selection (relative frequency)
in mixed clone infections, and whether heterologous immunity
less effectively controlled the virulent clone, we compared the fre-
quency of clone DS in mixed infections (Fig. 5).
We found that antigen immunization altered clone frequen-
cies. In sham-immunized mice, and those immunized with the
bi-allelic formulation, DS made up about 60% of all the parasites
present in the infections. Thus, immunization with a mixture of DS
and DK AMA-1 had negligible effect on clone frequency and thus
within-host selection (Fig. 5A; sham-immunized versus bi-allelic
immunization: F1,10 = 2.02, p=0.19). In contrast, immunizationwith
a single antigen reduced parasites in a clone-speciﬁcmanner, facili-
tating the heterologous clone (Fig. 5A andB; immunizing treatment
F1,10 = 105.54, p<0.001). Immunization with DK AMA-1 increased
the frequencyof cloneDS,whileDSAMA-1 immunization increased
the frequency of DK. These effects were essentially symmetrical.
Thus, there was no evidence that the more virulent clone, DS, was
less affected by heterologous immunization than was the less vir-
ulent clone DK.
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4. Discussion
In this study, we investigated (i) whether immunization with
a single or bi-allelic AMA-1 formulation afforded the host the
greatest protection from morbidity and parasite infection, (ii) how
these different vaccination regimes altered clonal compositions in
mixed infections, and (iii) whether a more virulent clone was less
successfully controlled by vaccine-induced protective responses.
Addressing each of these in turn, we found the following. (i)
Bi-allelic immunization did not generate better anti-morbidity
or anti-parasite protection than did single allele immunization.
Rather, immunization with one of the two variants alone (DS) pro-
vided the best protection. (ii) Both single variant immunizations
reduced the frequency of homologous clones in mixed infections;
bi-allelic immunization had no impact on within-host selection.
(iii) There was no evidence that the more virulent clone (DS) was
better at evading vaccine-induced immunity than was the less vir-
ulent clone.
Rightly, protecting individual hosts from morbidity is one of
the goals of malaria vaccines directed against the blood-stage of
infection. If infection densities are positively correlated with host
morbidity (virulence) [27] multi-allele vaccines could potentially
improve the health of the host by suppressing more of the parasite
population and reducing strain-speciﬁc responses. Subject to the
usual cautions about generalising from animal models (reviewed
in this context by Råberg et al. and Wargo et al. [60,61]), the
results presented here argue against that, and suggest that protec-
tive efﬁcacy may not be increased by including alternative variants
of AMA-1. Our in vivo observations are consistent with previous
results showing that immunization of rhesus monkeys with only
one of two PfAMA-1 variants is sufﬁcient to induce cross-protective
antibody responses as measured by GIA and ELISA assays in vitro
[52]. Our results are also consistent with another study which
demonstrated that mice and rabbits immunized with two allelic
variants of domain I and II of the full length AMA-1 ectodomain
from Indian P. falciparum isolates were able to inhibit in vitro para-
site growth, but to no greater extent than with either of the allelic
variants alone [53].
Our results also demonstrate strain-speciﬁc anti-parasite
responses (Fig. 4D) need not result in strain-speciﬁc protection
against disease (Fig. 3G and H). The observation that there are two
different types of anti-malarial responses – immunity against the
parasite itself and immunity against disease – is poorly understood
on a molecular basis although the distinction is widely appreci-
ated [62]. An explanation for the two different responses observed
here could be that the speciﬁcity of the anti-AMA-1 antibody
response lies with the generation of inhibitory antibodies which
may target the hypervariable region located around a conserved
hydrophobic pocket on domain I [63]. The presence of such anti-
bodies could determine the observed parasitaemias. For bi-allelic
immunizations there may exist a dominant epitope in one allelic
form of AMA-1. Thus, high titres of cross-reactive antibodies may
be sufﬁcient to lessen morbidity (hence the similar effects for
mono-and-bi-allelic vaccination on morbidity) but the inhibitory
antibodies are more effective at controlling parasite numbers by
inhibiting invasion. In our pilot studies we did not observe a dis-
proportional IgG2b antibody response to one of the immunizing
antigens (Fig. 1).However, since immunizationwithAMA-1 is likely
to induce a repertoire of IgG isotypes [58a,64–66] some of the
other isotypes may be sufﬁciently cross-reactive. An implication
of this may be that while strain-speciﬁc immunization may alter
allele frequencies in parasite populations, this need not have clini-
cal consequences in a vaccinated host. Changes in allele frequencies
without public health consequences have been seen in some other
diseases, such as pertussis (reviewed in [26]).
The ‘CombinationB’malaria vaccine, oneof the fewto reachﬁeld
trials, demonstrated strain-speciﬁc anti-parasite effects despite
being comprised of an allele of each of 3 asexual blood stage pro-
teins, MSP-1, MSP-2 and RESA (ring-infected erythrocyte surface
antigen) [29]. Of particular interest was that vaccination increased
the frequency of parasiteswith anMSP-2 genotypebelonging to the
FC27 allelic family. No representatives of this allelic family, which
had been found previously to be associated with severe morbid-
ity, were included in the vaccine [16,29,30]. Selection for the FC27
form of MSP-2 could have been because of strain-speciﬁc protec-
tion [15,31], or because the vaccine was less effective at protecting
against more virulent strains [26–28]. In the study we report here,
we looked at the relative proportion of the more virulent clone
in a mixed infection under the different immunization composi-
tions. In sham-immunized control mice and those which received
the bi-allelic immunization, the more virulent clone (DS) was pro-
portionally the most dominant. Thus, bi-allelic immunization did
not alter within-host selection. On the other hand, immunization
with a single AMA-1 variant did facilitate evasion of the heterolo-
gous clone in mixed infections. In our experiments, this effect was
symmetrical (Fig. 5), so that immunization with AMA-1 appears to
induce protective responses that are strain-speciﬁc and evasion is
independent of parasite virulence.
Nevertheless, selection for virulence could be an inadvertent
consequence of including just one allele from a given locus in a
vaccine, as apparently happened in the Combination B trial. As far
as we are aware, there are no reports that variants of AMA-1 have
different intrinsic virulence, so that the strain-speciﬁc immunity
against this locus we report here and that has been seen by others
[7,34], should not directly alter virulence. But caution is necessary
for all antigens involved in processes like cell invasion which are
associated with pathogenesis. Population-level association studies
for disease severity should be performed for all antigens included
in candidate vaccines. Should associations like that for MSP-2 be
found [30], we suggest on the basis of our results that there would
be a strong case for including all known variants at that locus in the
vaccine. This would not confer short-term clinical advantage, but it
would be the safest way to avoid inadvertent selection for virulent
variants, which would put unvaccinated people at greater risk.
More generally, though, we still have some way to go to under-
stand the potential for vaccine-driven virulence evolution, even in
the P. chabaudi model. One experimental study demonstrated that
parasites from a single P. chabaudi clone serially passaged through
whole-parasite immunized mice evolved to be more virulent than
those evolved in naive hosts [28]. That study was the ﬁrst to show
under controlled conditions that immunization can favour the evo-
lution of more virulent parasites. The implication was that more
virulent variants had a selective advantage in immunized hosts. In
the study we report here, which did not involve serial passage, we
saw no signs of such an advantage. DS, the more virulent clone,
dominated in mice immunized with the bi-allelic form, but to the
same extent as in non-immunized mice. In single antigen immu-
nized mice, strain-speciﬁc immunity dominated with symmetrical
effects for both clones. Competition experiments with other P.
chabaudi clones also failed to ﬁnd an increased advantage to vir-
ulence in immunized hosts [67]. It may be that the accelerated
evolution of virulence seen during serial passage in immunized
hosts [28,68] is a feature of selection of virulence variants on an
antigenically identical background. In future experiments, we will
serially passage single P. chabaudi clones through AMA-1 immu-
nized and naïve mice to determine whether vaccination can evolve
virulence to be greater when measured in naïve hosts.
Our experiments concerned antigenic polymorphism at a single
target antigen. Considerably more work has focused on vaccines
combining single variants frommultiple antigenic loci [1,69,70]. For
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example, animal and human phase I trails have shown safety, toler-
ability and immunogenecity of formulations containingAMA-1 and
MSP-1 [1,71–73]. Moreover, such ‘multi-valent’ vaccines have been
shown to reduce parasitaemias in mice of distinct MHC haplotypes
[74] and against infections with different parasite strains as well
as subspecies of different virulence [75]. Thus, multi-valency may
be required to induce antibody responses against a repertoire of
polymorphic parasite antigens [64,66,76–81] in thehumanoutbred
population exposed to multiple parasite genotypes [29,78,82–84].
We suspect that multi-valent vaccines will prove to be a more efﬁ-
cient means of generating protection against the widest range of
parasite genotypes. Certainly, we found no evidence that the anti-
morbidity and anti-parasitic potency of a malaria vaccine would
be enhanced by increasing the number of variants of a particular
antigen.
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